Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

Dow Jones05-09

 
Operating expenses 
   General and administrative        $     1,615,452   $  1,683,817 
   Research and development                  842,832      1,091,733 
                                        ------------    ----------- 
 
      Total operating expenses             2,458,284      2,775,550 
                                        ------------    ----------- 
 
Other (income) and expenses 
   Unrealized loss (gain)                      6,509        (20,427) 
   Realized and accrued interest 
    income                                  (137,513)      (152,054) 
                                        ------------    ----------- 
      Total other income                    (131,004)      (172,481) 
                                        ------------    ----------- 
Net loss                             $    (2,327,280)  $ (2,603,069) 
                                        ============    =========== 
 
 
Loss per ADS 
   Basic                             $         (1.11)  $      (4.09) 
   Fully-diluted                     $         (1.11)  $      (4.09) 
 
Weighted average number of ADS's outstanding 
   Basic                                   2,103,292        637,217 
   Fully-diluted                           2,103,292        637,217

(END) Dow Jones Newswires

May 09, 2024 08:30 ET (12:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434809443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-09 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2434809443","market":"fut","top_or_hot":-1,"title":"Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \nOperating expenses \n   General and administrative        $     1,615,452   $  1,683,817 \n   Research and development                  842,832      1,091,733 \n                                        ------------    ----------- \n \n      Total operating expenses             2,458,284      2,775,550 \n                                        ------------    ----------- \n \nOther (income) and expenses \n   Unrealized loss (gain)                      6,509        (20,427) \n   Realized and accrued interest \n    income                                  (137,513)      (152,054) \n                                        ------------    ----------- \n      Total other income                    (131,004)      (172,481) \n                                        ------------    ----------- \nNet loss                             $    (2,327,280)  $ (2,603,069) \n                                        ============    =========== \n \n \nLoss per ADS \n   Basic                             $         (1.11)  $      (4.09) \n   Fully-diluted                     $         (1.11)  $      (4.09) \n \nWeighted average number of ADS's outstanding \n   Basic                                   2,103,292        637,217 \n   Fully-diluted                           2,103,292        637,217 \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 09, 2024 08:30 ET (12:30 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-09 20:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Operating expenses \n   General and administrative        $     1,615,452   $  1,683,817 \n   Research and development                  842,832      1,091,733 \n                                        ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QNRX","symbol_name":"Quoin Pharmaceuticals","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2434809443","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434809443","pubTimestamp":1715257800,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies. U.S. and International patent filed for novel Netherton Syndrome combination product. ASHBURN, Va., May 09, 2024  -- Quoin Pharmaceuticals Ltd.  , a clinical stage, specialty pharmaceutical company focused on developing and commercializing novel treatments for rare and orphan diseases, today provides a business update and announces financial results for the first quarter ended March 31, 2024.During the quarter, we expanded our intellectual property portfolio by the filing of US and International patent applications for a novel combination product as a treatment for Netherton Syndrome. We continue to explore additional patent opportunities for the product in both clinical and in the manufacturing of the active ingredient and finished product. Finally, via the combination of a successful public offering and the execution of an equity line of credit arrangement, we have extended our cash runway into late ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QNRX":"Quoin Pharmaceuticals","BK4139":"生物科技"},"translate_title":"新闻稿：Quoin Pharmaceuticals提供公司最新消息并公布2024年第一季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNRX":1},"content_text":"Operating expenses \n   General and administrative        $     1,615,452   $  1,683,817 \n   Research and development                  842,832      1,091,733 \n                                        ------------    ----------- \n \n      Total operating expenses             2,458,284      2,775,550 \n                                        ------------    ----------- \n \nOther (income) and expenses \n   Unrealized loss (gain)                      6,509        (20,427) \n   Realized and accrued interest \n    income                                  (137,513)      (152,054) \n                                        ------------    ----------- \n      Total other income                    (131,004)      (172,481) \n                                        ------------    ----------- \nNet loss                             $    (2,327,280)  $ (2,603,069) \n                                        ============    =========== \n \n \nLoss per ADS \n   Basic                             $         (1.11)  $      (4.09) \n   Fully-diluted                     $         (1.11)  $      (4.09) \n \nWeighted average number of ADS's outstanding \n   Basic                                   2,103,292        637,217 \n   Fully-diluted                           2,103,292        637,217 \n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 09, 2024 08:30 ET (12:30 GMT)","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434809443"}